The Scientist

» clinical trials and disease/medicine

Most Recent

image: DNA-Based Zika Vaccine Reaches Phase 2

DNA-Based Zika Vaccine Reaches Phase 2

By | April 4, 2017

An NIAID-sponsored clinical trial advances beyond safety testing.

0 Comments

At the annual American Association for Cancer Research meeting, researchers discuss the importance of understanding the epigenetic contributors to cancer progression and treatment response.

0 Comments

image: Contributors

Contributors

By | April 1, 2017

Meet some of the people featured in the April 2017 issue of The Scientist.

0 Comments

image: Hitting It Out of the Park

Hitting It Out of the Park

By | April 1, 2017

Cancer can be as evasive and slippery as a spitball, but new immunotherapies are starting to connect.

0 Comments

image: Location, Location, Location

Location, Location, Location

By | April 1, 2017

Since first proposing that a cell’s function and biology depend on its surroundings, Mina Bissell continues to probe the role of the extracellular matrix.

3 Comments

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

Measuring PD-L1 levels was a great start. Now we need to quantify more protein biomarkers, assess the tumor mutational landscape, and examine immune cell signatures, too.

0 Comments

image: Circadian Rhythms Influence Treatment Effects

Circadian Rhythms Influence Treatment Effects

By | April 1, 2017

Across many diseases, taking medication at specific times of day may make the therapy more effective.

1 Comment

image: Infographic: Circadian Clock Affects Health and Disease

Infographic: Circadian Clock Affects Health and Disease

By | April 1, 2017

The body's rhythms could affect numerous ailments as well as how people respond to treatments.

0 Comments

image: Rethinking a Cancer Drug Target

Rethinking a Cancer Drug Target

By | March 26, 2017

The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

0 Comments

Popular Now

  1. Man Receives First In Vivo Gene-Editing Therapy
  2. Researchers Build a Cancer Immunotherapy Without Immune Cells
  3. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  4. Research Links Gut Health to Neurodegeneration
    The Nutshell Research Links Gut Health to Neurodegeneration

    Rodent studies presented at the Society for Neuroscience meeting this week tie pathologies in the gastrointestinal tract or microbiome composition with Parkinson’s and Alzheimer’s diseases.

RayBiotech